IPO - INSPIRE VETERINARY PARTNERS, INC.

Form Type: DRS

Filing Date: 2025-06-20

Corporate Action: Ipo

Type: New

Accession Number: 000121390025056027

Filing Summary: On June 20, 2025, Inspire Veterinary Partners, Inc. confidentially submitted a Draft Registration Statement under the Jumpstart Our Business Startups Act in preparation for its initial public offering (IPO). The registration statement indicates plans to raise up to $5,000,000 through the sale of securities, specifically Units which consist of Class A common stock and associated warrants. The Company aims to continue expanding its operations, having completed the acquisition of several veterinary facilities, including the Debary Animal Clinic. This offering follows the Company's previous IPO on August 31, 2023. The shares are intended to be listed on The Nasdaq Capital Market under the symbol 'IVP'. Risks associated with the offering including potential compliance issues with Nasdaq and insufficient operating history affecting profitability are acknowledged. The prospectus outlines details of the Units offered, including pricing and terms, as well as risk factors investors should consider before participating.

Form Type: 424B5

Filing Date: 2024-12-23

Corporate Action: Ipo

Type: New

Accession Number: 000121390024111433

Filing Summary: Inspire Veterinary Partners, Inc. has filed a prospectus supplement for an At The Market Offering Agreement with H.C. Wainwright & Co., LLC to offer up to $25,000,000 of its Class A common stock. The stock is listed on the Nasdaq Capital Market under the symbol 'IVP'. The most recent sale price before this offering was $0.1870 per share. The offering allows for sales at market prices directly through Wainwright or other market makers, and the company will incur a fixed commission of 3% on the sales. The funds raised will be used for working capital, repayment of debt, and potential acquisitions, although no specific deals are currently pending. The company's market value held by non-affiliates exceeded $75 million, qualifying it for a registration statement on Form S-3, and they are not subject to certain offering limits. The document also outlines recent compliance issues with Nasdaq regarding minimum bid requirements and shareholder approval rules for previous transactions. There are various risk factors associated with this offering, including the potential for delisting from Nasdaq if compliance is not regained by June 16, 2025.